Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Iclusig ponatinib regulatory update

December 15, 2014 8:00 AM UTC

Australia’s Therapeutic Goods Administration ( TGA) approved Iclusig ponatinib from Ariad to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Ariad plans to launch the pan- BCR-ABL tyrosine kinase inhibitor (TKI) in Australia in early 2015. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article